BioInvent International AB stock analysis
BioInvent International AB (0H22) Share Price & Analysis
0H22 Stock Chart & Stats
- Day’s Range
- SEK 3.00 - SEK 3.00
- 52-Week Range
- SEK 2.25 - SEK 34.18
- Previous Close
- SEK 3.23
- Volume
- N/A
- Average Volume (3M)
- 11.67K
- Market Cap
- SEK 201.36M
- Enterprise Value
- SEK 1.30B
- Total Cash (Recent Filing)
- SEK 224.56M
- Total Debt (Recent Filing)
- SEK 19.33M
- Price to Earnings (P/E)
- ―
- Beta
- 0.44
- Next Earnings
- Mar 04, 2027 (Est.)
- EPS Estimate
- -1.07
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Clinical And Regulatory Progress
FDA Fast Track designations and continued clinical advancement strengthen BI-1808’s development position in cancers with high unmet need. These milestones can improve regulatory interaction, support future partnering discussions, and provide a clearer path toward later-stage development if efficacy remains supportive.
Conservative Leverage
Very low leverage reduces fixed financial obligations and preserves flexibility while BioInvent funds clinical programs. A conservatively financed balance sheet gives management more room to prioritize development spending, absorb operating volatility, and pursue partnerships without the added pressure of substantial debt service.
Proprietary Oncology Platform
Ownership of proprietary antibody discovery capabilities and specialized immune-oncology expertise provides a foundation for generating multiple therapeutic candidates rather than relying on a single asset. This platform approach can support pipeline renewal, collaboration opportunities, and durable strategic relevance in cancer drug development.
Bears Say
Accelerating Cash Burn
Persistent and worsening cash consumption means BioInvent must continually secure external funding or partnership proceeds to sustain operations and clinical trials. This reduces financial resilience, limits strategic flexibility, and increases the consequences of delays in development, approvals, or transactions.
Persistent Operating Losses
Deep and recurring operating losses show that current revenue streams do not cover the cost of advancing the pipeline. Until products or collaborations generate more dependable economics, profitability remains dependent on successful clinical execution, milestone income, licensing, or additional financing.
Dependence On Partnering
Reliance on partners to continue BI-1206 development can reduce BioInvent’s control over timing, funding, and program scope. If a suitable partner is not secured, clinical progress may slow or require additional equity financing, making pipeline advancement more vulnerable to external negotiation outcomes.
BioInvent International AB News
0H22 FAQ
What was BioInvent International AB’s price range in the past 12 months?
What is BioInvent International AB’s market cap?
When is BioInvent International AB’s upcoming earnings report date?
How were BioInvent International AB’s earnings last quarter?
Is BioInvent International AB overvalued?
Does BioInvent International AB pay dividends?
What is BioInvent International AB’s EPS estimate?
How many shares outstanding does BioInvent International AB have?
What happened to BioInvent International AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of BioInvent International AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
BioInvent International AB
BioInvent International AB (publ) is a clinical-stage Swedish company dedicated to discovering, researching, and developing immunomodulatory antibodies for global cancer treatment, with reach across Sweden, Europe, the United States, and Japan. Its most advanced therapeutic candidate, BI-1206, targets non-Hodgkin lymphoma and various solid tumors. The company's diverse pipeline also features developments aimed at tumor-associated myeloid cells and cancer-associated regulatory T cells, which play a role in modulating the immune system, alongside BT-001 for solid tumors. Furthermore, BioInvent is progressing BI-1808 and BI-1910, a pair of anti-TNFR2 antibodies, designed to combat solid tumors and cutaneous T-cell lymphoma. Strategic collaborations are integral to its operations; these include a partnership with Pfizer Inc. for antibody development against tumor-associated myeloid cells, a co-development effort with Transgene involving multi-functional oncolytic viruses for solid tumors, and an agreement with Merck for the clinical advancement and supply of BI-1808. Established in 1996, BioInvent is based in Lund, Sweden.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Martin Welschof
- Employees
- 107
- Website
- www.bioinvent.com
- Address
- The Gamma Building, Lund, SN, 223 70, SE
BioInvent International AB (0H22) Earnings & Revenues
0H22 Company Deck
0H22 Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive, supported by encouraging BI-1808 response and progression-free survival data, FDA Fast Track designations, an ESMO Best Poster Award, planned randomized development, and a potentially extended cash runway through the end of 2027 if the covered portion of the rights issue is completed. The company nevertheless reported a substantial net loss, a sharp year-to-date sales decline due largely to the prior-year milestone comparison, planned workforce reductions, dependence on financing and partnering, and delays in BI-1206 data maturation.
View all GB:0H22 earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 1 | 16 |
| Technical Analysis | 5 | 1 | 4 |
| Moving Averages | 0 | 0 | 12 |
